Active and passive immunity, vaccine types, excipients and licensing
about
Recent Advances in Subunit Vaccine CarriersPlant-derived immunomodulators: an insight on their preclinical evaluation and clinical trialsImmunization with L. sigmodontis microfilariae reduces peripheral microfilaraemia after challenge infection by inhibition of filarial embryogenesisRecent advances of vaccine adjuvants for infectious diseasesBeyond causes of death: The social determinants of mortality among children aged 1-59 months in Nigeria from 2009 to 2013The Therapeutic Benefit of Bacterial Membrane Vesicles.Long term follow-up study to evaluate immunogenicity and safety of a single dose of live attenuated hepatitis a vaccine in children.Novel antigen delivery systems.Microbial synthetic biology for human therapeutics.Potent In Vitro and In Vivo Activity of Plantibody Specific for Porphyromonas gingivalis FimA.Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.Passive immunization with hyperimmune egg-yolk IgY as prophylaxis and therapy for poultry diseases--A review.Anti-inflammatory Potential of Quercetin-3-O-β-D-("2"-galloyl)-glucopyranoside and Quercetin Isolated from Diospyros kaki calyx via Suppression of MAP Signaling Molecules in LPS-induced RAW 264.7 Macrophages.Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application.Tetanus vaccination is associated with differential DNA-methylation: Reduces the risk of asthma in adolescence.Innate signaling by mycobacterial cell wall components and relevance for development of adjuvants for subunit vaccines.Standardized extract of Tinospora crispa stimulates innate and adaptive immune responses in Balb/c mice.Postvaccinal neurological complications.Partial protection against enterovirus 71 (EV71) infection in a mouse model immunized with recombinant Newcastle disease virus capsids displaying the EV71 VP1 fragment.Maternal Vaccination. Immunization of Sows during Pregnancy against ETEC Infections.Tetanus immunity in construction workers in Italy.Baculovirus Surface Display of Immunogenic Proteins for Vaccine DevelopmentIn planta expression of nanobody-based designer chicken antibodies targeting Campylobacter
P2860
Q26750929-7F7BB795-9C40-4677-B35F-196C9E887C0CQ26784434-38288AA5-123A-4C3B-B7E0-A9673D3003D6Q27305577-9CAF68E6-DAB4-46CB-A858-C09BB209B14DQ28083679-EE1D99DD-D035-42D6-ADE7-0A41612187A0Q33745796-A4D53B62-3ED0-4DA6-808B-02D41FDE62B6Q33839021-C2BFD26E-E1F7-4786-B955-68C99A9169C4Q35887102-2CB8050A-945F-4E20-96C6-7D908B0E1681Q35947894-DD6C3BE6-3ADC-4647-8891-94BE84A94319Q36179139-719B3CC6-E4BA-4CF7-BDD1-2E38AF3DB4BFQ36764378-225B6924-FD26-453F-8CDD-0694D4C931D8Q38554795-7470B028-92C0-4530-8CF5-B47EE5E3B0C5Q38633565-22388C07-698F-4D4F-B02E-09BE6E997053Q38744744-05447BDC-0874-41E0-8426-598C3595C338Q38957782-A836CACB-5005-4CA5-844A-221665867D83Q39170904-4AD1B6F9-95BD-407A-8BD7-453FE382579AQ39748955-BD7787BA-2C30-4880-9457-B96140EE420AQ40807471-B8BAFF0F-15B6-4CC9-8102-3C9A21C2A7D0Q42261125-54EEBBA5-1431-4788-B617-BC25DA25039CQ45364181-53DA9B03-D014-4878-A325-1B49EBBFD1A6Q46246924-4EA31304-0B69-4E4D-ABBE-E07B38DEC547Q46251877-02D8C3D0-9D39-4A1A-BAFE-8E68CC3F3961Q56514706-3BB7B744-1BFE-402D-84E1-D4076CB15DFFQ58691849-83E281D7-CF9A-4426-B360-3147122AA9F4
P2860
Active and passive immunity, vaccine types, excipients and licensing
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Active and passive immunity, vaccine types, excipients and licensing
@ast
Active and passive immunity, vaccine types, excipients and licensing
@en
Active and passive immunity, vaccine types, excipients and licensing
@nl
type
label
Active and passive immunity, vaccine types, excipients and licensing
@ast
Active and passive immunity, vaccine types, excipients and licensing
@en
Active and passive immunity, vaccine types, excipients and licensing
@nl
prefLabel
Active and passive immunity, vaccine types, excipients and licensing
@ast
Active and passive immunity, vaccine types, excipients and licensing
@en
Active and passive immunity, vaccine types, excipients and licensing
@nl
P2860
P3181
P356
P1476
Active and passive immunity, vaccine types, excipients and licensing
@en
P2093
David Baxter
P2860
P3181
P356
10.1093/OCCMED/KQM110
P407
P577
2007-12-01T00:00:00Z